Navigation Links
Osteoporosis – A New Treatmen

Increasing the activity of a protein called NFATc1 tends to cause massive bone accumulation that target the drugs used to treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI predoctoral fellow Monte Winslow reports.

In vertebrates, bone is constantly being formed and being broken down throughout life. Cells called osteoclasts continuously degrade bone, while cells called osteoblasts replenish it.

‘Ideally, they are perfectly balanced,’ said Crabtree, the senior author of the study. ‘Over the course of a lifetime, if everything goes well, we'll maintain almost exactly identical bone mass.’ However, if the balance is upset, and more bone is destroyed than formed, osteoporosis results, increasing the risk of fractures.

The new study arose from the researchers' curiosity about reports that patients who were treated with the drug cyclosporine – often given to suppress the immune system before organ transplants – tended to lose bone mass. Those patients were also at increased risk of bone fractures, said first author Winslow, who led the study as an HHMI predoctoral fellow in Crabtree's lab. Winslow is now working as a postdoctoral fellow in the lab of HHMI investigator Tyler Jacks at the Massachusetts Institute of Technology.

Cyclosporine inhibits a signaling protein complex known as calcineurin, which chemically modifies the NFATc family of proteins. This modification changes its shape. With its new shape, NFATc can move into the nucleus of the cell, where it can trigger the activation of many genes. Although initially shown to regulate immune cell function, NFATc also functions in other cells to regulate heart development, blood vessel formation, neural development and function, and muscle development. Its function seems to depend on the time and place of its activation, like a context-sensitive key on a computer. In bone, it is NFATc1 that seems particularly important.

Since people with suppressed cal cineurin/NFATc activity experience bone loss, Winslow, Crabtree, and their colleagues wanted to see whether this pathway would be important in bone development and function as well. They studied mutant mice in which the NFATc1 in osteoblasts had been modified so that it could move more easily to the nucleus and become a little more active than usual.

Mice with the hyperactive NFATc in their osteoblasts had an immense increase in bone mass compared to normal mice, suggesting that the balance between bone formation and breakdown had tipped.

When the researchers examined the cells in these mice, they found that up-regulating NFATc signaling in osteoblasts increased the numbers of both types of bone cells. ‘It was clear that increased NFATc activity in osteoblasts influenced both osteoblasts and osteoclasts,’ Winslow said.

The researchers found that mice that showed enhanced NFATc activity in their osteoblasts had many more of these bone-forming cells, which explained the increase in bone mass. They also found a possible explanation for why there were more bone-destroying osteoclasts. Osteoblasts with hyperactive NFATc expressed higher levels of inflammatory proteins called chemokines, which promote osteoclast development.

‘Osteoblasts produce factors that recruit the progenitors of osteoclasts, and so when osteoblast numbers go up, osteoclast numbers go up,’ Crabtree said. This link between osteoblast and osteoclast numbers explains in part how the two types of cells normally stay balanced in animals, he added.

Mice with abnormally active NFATc probably develop so much bone mass because this delicate balance between osteoblasts and osteoclasts has been altered, Crabtree suggested. In the mutant mice, ‘there's also a huge increase in osteoclasts, but they never catch up,’ he said. ‘The balance has been tipped.’

This imbalance between bone formation and degradation could potentially be recreated by drug tre atments for osteoporosis, Crabtree said. Very little NFATc1 must be activated to build extra bone, Winslow noted, which means that it may be possible to up-regulate the calcineurin/NFATc pathway to promote bone formation without disturbing other organ systems that use this same pathway.

‘The results were dramatic, yet the molecular alteration is very, very minimal,’ Crabtree said. NFATc1 in the mice that developed extra bone mass was only 10 percent more active than it is in normal mice.

The researchers are now screening chemical libraries for small molecules that could increase NFATc just enough to promote bone formation in people with osteoporosis, without causing undesirable side effects. ‘If you could find a small molecule that would flip 10 percent of the existing NFATc into the active form,’ Crabtree said, ‘you could favor the formation of osteoblasts and make stronger bones.’

(Surce: Eurekalert)
'"/>




Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Osteoporosis Drugs: right time to take-off
4. Fluoride Found Effective in Osteoporosis
5. Mutation connected to Osteoporosis
6. Osteoporosis associated with Childhood Cancer
7. A treatment for Osteoporosis
8. Osteoporosis could be caused by irregular periods
9. Back exercises reduces Osteoporosis
10. Osteoporosis and kidney stones gene marker identified
11. The Answer To Prevent Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... to catalyze conversations in support of bold systems change models helping to achieve ... an event on September 21, 2017, “We the Future: Accelerating Sustainable Development Solutions” ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced today that for ... among the fastest-growing private companies in the U.S., putting it in the top 10 ... applied to the Inc. 5000 over the years, only a fraction have ...
(Date:8/17/2017)... ... 2017 , ... Dr. Charles W. Grimsley’s new book ... 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed with posttraumatic ... through a progressive journey toward healing. This book will help readers learn to ...
(Date:8/17/2017)... ... August 17, 2017 , ... Momkus McCluskey Roberts LLC recently ... is a member of the firm’s Commercial Litigation and Employment Law groups. , Ms. ... of knowledge in matters of employment litigation, commercial litigation and business disputes. Her experience ...
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates that circa 79 percent ... cited deficiencies in data integrity. The FDA outlines their expectations for quality critical instrumentation ... as part of the Beckman Coulter Life Sciences Virtual Trade Show Virtual ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... the quarter ended June 30, 2017.  All comparisons, unless otherwise ... Second Quarter 2017 Highlights ... to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
Breaking Medicine Technology: